CGEN Compugen Ltd.
Compugen Ltd. (CGEN) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.0% since its last earnings release on August 3, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Compugen Ltd.
Compugen Ltd is a drug discovery and development company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology.
Sector
Healthcare
Industry
Biotechnology